Role for the nicotinic cholinergic system in movement disorders; therapeutic implications

摘要: A large body of evidence using experimental animal models shows that the nicotinic cholinergic system is involved in control movement under physiological conditions. This work raised question whether dysregulation this may contribute to motor dysfunction and drugs targeting acetylcholine receptors (nAChRs) be therapeutic benefit disorders. Accumulating preclinical studies now show acting at nAChRs improve drug-induced dyskinesias. The general nAChR agonist nicotine, as well several agonists (varenicline, ABT-089 ABT-894), reduces l-dopa-induced abnormal involuntary movements or dyskinesias up 60% parkinsonian nonhuman primates rodents. These are potentially debilitating arise a complication l-dopa therapy for Parkinson's disease. In addition, nicotine varenicline decrease antipsychotic-induced rodent tardive dyskinesia. Antipsychotic-induced frequently side effect chronic drug treatment schizophrenia, psychosis other psychiatric Preclinical clinical also improves balance coordination various ataxias. Lastly, has been reported attenuate dyskinetic symptoms Tourette's disorder. Several subtypes appear these beneficial effects including α4β2*, α6β2* α7 (the asterisk indicates possible presence subunits receptor). Overall, above findings, coupled with nicotine's neuroprotective effects, suggest have potential future development